Caligan Partners LP
Top Portfolio Positions
25 positions ·
$1,620,686,473 total
· as of Mar 31, 2026
| Ticker | Company | Shares | Value (USD) | % of Portfolio | Open |
|---|---|---|---|---|---|
| LQDA |
Liquidia Corp
Healthcare
|
8,118,892 | $306,406,984 | 18.91% | |
| RVMD |
Revolution Medicines, Inc.
Healthcare
|
1,881,708 | $182,996,103 | 11.29% | |
| ABVX |
Abivax S.A.
Healthcare
|
1,461,924 | $162,785,237 | 10.04% | |
| PCVX |
Vaxcyte, Inc.
Healthcare
|
2,060,719 | $119,748,381 | 7.39% | |
| XENE |
Xenon Pharmaceuticals Inc.
Healthcare
|
1,393,027 | $81,004,520 | 5.00% | |
| MLYS |
Mineralys Therapeutics, Inc.
Healthcare
|
2,772,654 | $75,111,196 | 4.63% | |
| LBRX |
Lb Pharmaceuticals Inc
Healthcare
|
2,876,140 | $70,925,612 | 4.38% | |
| EXEL |
Exelixis, Inc.
Healthcare
|
1,553,262 | $66,619,407 | 4.11% | |
| SABS |
SAB Biotherapeutics, Inc.
Healthcare
|
15,934,414 | $61,028,804 | 3.77% | |
| CGON |
CG Oncology, Inc.
Healthcare
|
900,000 | $60,912,000 | 3.76% |
Portfolio Trend
14 quarters · across all stocks
Holdings in MLYS
Shares Held
Position Value (USD)
9 quarters on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $75,111,196 | 2,772,654 | Shares | Sole | 2026-05-15 | |
| 2025-12-31 | $100,619,613 | 2,772,654 | Shares | Sole | 2026-02-17 | |
| 2025-12-31 | $83,408,936 | 2,298,400 | Put | Sole | 2026-02-17 | |
| 2025-09-30 | $105,139,039 | 2,772,654 | Shares | Sole | 2025-11-14 | |
| 2025-06-30 | $27,294,772 | 2,017,352 | Shares | Sole | 2025-08-14 | |
| 2025-03-31 | $34,136,711 | 2,149,667 | Shares | Sole | 2025-05-15 | |
| 2024-12-31 | $12,447,318 | 1,011,155 | Shares | Sole | 2025-02-14 | |
| 2024-09-30 | $11,881,787 | 981,155 | Shares | Sole | 2024-11-14 | |
| 2024-06-30 | $8,725,368 | 745,758 | Shares | Sole | 2024-08-14 | |
| No 13F history on record for this holder in this stock. | ||||||